Technical Standards and Guidelines for Fragile X: The First of a Series of Disease-Specific Supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics [PDF]
Anne Maddalena+11 more
openalex +1 more source
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé+7 more
wiley +1 more source
Patient care practices for LGBTQ+ individuals in clinical genetics: A scoping review. [PDF]
Zayhowski K+6 more
europepmc +1 more source
Linear Diagnostic Procedure Elicited by Clinical Genetics and Validated by mRNA Analysis in Neuronal Ceroid Lipofuscinosis 7 Associated with a Novel Non-Canonical Splice Site Variant in MFSD8. [PDF]
Pasquetti D+10 more
europepmc +1 more source
Clinical signs, histopathology and genetics of experimental transmission of BSE and natural scrapie to sheep and goats [PDF]
James D. Foster+4 more
openalex +1 more source
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM
CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.
Julia Latowska‐Łysiak+14 more
wiley +1 more source
Understanding the clinical genetics of kidney stone disease using the Natera Renasight panel. [PDF]
Baca AL+13 more
europepmc +1 more source
A unique service: how an embedded psychology team can help patients and genetics clinicians within a clinical genetics service. [PDF]
Firth C+5 more
europepmc +1 more source
Neuroblastoma tumour genetics: clinical and biological aspects [PDF]
Nick Bown
openalex +1 more source
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini+10 more
wiley +1 more source